Results 51 to 60 of about 5,544 (172)

Management of gout: Primary care approach

South African Family Practice, 2009
Great strides have been made in understanding gout as a disease over the centuries. Despite these advances, reports suggest that the management of gout is relatively sub-optimal at the primary care level.
Olufemi Omole, Gboyega A. Ogunbanjo
doaj   +1 more source

Neuregulin 4‐dependent MAPK amplification mediates urate‐induced β‐cell dysfunction

Journal of Diabetes Investigation, EarlyView.
Hyperuricemia impairs glucose homeostasis by inducing pancreatic β‐cell apoptosis without insulin resistance. In male Uox‐KO mice, urate upregulates Nrg4, which amplifies MAPK signaling and drives β‐cell death. Thus, hyperuricemia disrupts glucose metabolism via the Nrg4‐MAPK axis.
Yunyang Wang, Kun Zhang, Zhiyuan Li, Shuhui Hu, Yiru Zhang, Yulei Zhao, Xiaohan Liu, Jie Lu   +7 more
wiley   +1 more source

Critical appraisal of the role of pegloticase in the management of gout

Open Access Rheumatology: Research and Reviews, 2012
Hang-Korng Ea,1,2 Pascal Richette1,21Hôpital Lariboisière, Rheumatology Department, Paris, France; 2University of Paris Diderot, Sorbonne Paris Cité, Paris, FranceAbstract: Gout is a debilitating disease secondary to ...
Ea HK, Richette P
doaj  

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

The Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor, Nycolle I. S. Souza, Bruno G. Anjos, Stephen G. Matthews, Enrrico Bloise   +4 more
wiley   +1 more source

Urate-lowering therapy in maintenance hemodialysis: focusing on gout burden rather than serum urate alone

Renal Replacement Therapy
Background Whether asymptomatic hyperuricemia should trigger pharmacologic intervention in maintenance hemodialysis remains unresolved. This question differs fundamentally from hyperuricemia management in the general population or in nondialysis chronic ...
Yoshitaka Furuto, Daiki Yoshino, Akio Namikawa, Dai Sato, Yuko Shibuya   +4 more
doaj   +1 more source

Northeast China Traditional Kimchi (Paocai) Probiotic Resources Metabolized Uric Acid and Relieved Hyperuricemia in Mice

eFood, Volume 7, Issue 4, August 2026.
Traditional fermented Kimchi “paocai”, commonly consumed in Northeast China, was screened for probiotic resources capable of degrading uric acid in vitro and alleviating hyperuricemia in a mouse model. Abstract Current pharmacological therapies for hyperuricemia (HUA), though effective, pose safety concerns, including allopurinol‐induced severe dermal ...
Aman Khan, Xiaoyu Wang, Binyu Cui, Xiaoqian Zhou, Yingying Lu, Lifang Ma, Qizhuang Li, Dechun Yin, Weidong Wang   +8 more
wiley   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, Volume 32, Issue 26, 11 July 2026.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management

Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley   +1 more source

Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real‐World Data Screening and in Vitro Validation

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
Drug repositioning analysis identifies candidate therapeutic agents for Alzheimer’s diseaseand supports further mechanistic and translational investigation. ABSTRACT Drug development for Alzheimer's disease (AD) remains challenging, with only a 0.4% success rate from Phase I trials to regulatory approval.
Sho Sakagami, Yuya Yoshida, Shota Uemura, Taisei Kumamoto, Ryotaro Tsukamoto, Takumi Nishi, Shimpei Kawano, Kohei Fukuoka, Hanami Ino, Kengo Hamamura, Shigehiro Ohdo, Naoya Matsunaga   +11 more
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source